![siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/04/clot-CCWiki-350x250.jpg)
Tenecteplase not associated with visual improvement in central retinal artery occlusion
1. In this randomized controlled trial of adults with central retinal artery occlusion, tenecteplase administration shortly after symptom onset did ...
Tag: alteplase
#VisualAbstract: Alteplase Improves Outcomes in Acute Ischemic Stroke
Click here to read this study in JAMA. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Delayed alteplase has clinical benefits in posterior circulation stroke outcomes
1. In this randomized controlled trial of patients with posterior circulation stroke not for thrombectomy, treatment with alteplase 4.5 to ...
#VisualAbstract: Tenecteplase is Non-Inferior to Alteplase for Acute Ischemic Stroke within 4.5 Hours of Onset
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Intravenous tenecteplase shows no benefit in minor ischaemic stroke with intracranial occlusion
1. Return to baseline function was comparable in tenecteplase and standard-of-care groups. 2. More deaths and intracranial hemorrhages were reported ...
Reteplase associated with improved functional outcomes in ischemic stroke patients
1. In a randomized controlled trial of patients who suffered an acute ischemic stroke, the reteplase group reported a greater ...
#VisualAbstract: Intravenous thrombolysis plus endovascular treatment may be more efficacious for acute ischemic stroke
1. The 90-day modified Ranking Scale score was comparable for patients in intravenous thrombolysis plus endovascular treatment versus endovascular treatment ...
Intravenous thrombolysis plus endovascular treatment may be more efficacious for acute ischemic stroke
1. The 90-day modified Ranking Scale score was comparable for patients in intravenous thrombolysis plus endovascular treatment versus endovascular treatment ...
#VisualAbstract: Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke
1. The ARAMIS trial revealed that the rate of favourable neurologic function at 90 days was 93.8% among patients assigned ...
Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke – the ARAMIS trial
1. The ARAMIS trial revealed that the rate of favourable neurologic function at 90 days was 93.8% among patients assigned ...
